SAN CLEMENTE, Calif., Oct. 1 -- Biolase Technology Inc. has obtained clearances from the US Food and Drug Administration to market the company's new lightweight diode lasers, TwiLite and HyLite, for use in dental cosmetic and soft tissue procedures. Biolase also received clearances that include indications for use of the new lasers in arthroscopy, gastroenterology, ENT, general surgery, plastic surgery, dermatology, GI/GU, gynecology, podiatry, neurosurgery, ophthalmology, urology, and pulmonary surgery.According to Jeffrey W. Jones, president and CEO of Biolase, cosmetic and painless procedures represent the fastest-growing and most profitable segment of the dental market. Jones also noted that the new lasers' consumable handpieces, fibers, and tips would provide the company with a recurring stream of revenue.